{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T05:05:31Z","timestamp":1745643931144,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,12]],"date-time":"2017-02-12T00:00:00Z","timestamp":1486857600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Taiho Pharmaceutical, Eli Lilly Japan"},{"name":"Taiho Pharmaceutical, Eli Lilly Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40792-017-0303-5","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T18:21:26Z","timestamp":1486837286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A pathological complete response after combined chemotherapy of gemcitabine and S-1 in advanced biliary tract cancer with para-aortic lymph nodes metastasis: a case report"],"prefix":"10.1186","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-5242","authenticated-orcid":false,"given":"Takeshi","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kamma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,12]]},"reference":[{"key":"303_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00534-008-0015-0","volume":"16","author":"S Miyakawa","year":"2009","unstructured":"Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16:1\u20137.","journal-title":"J Hepatobiliary Pancreat Surg."},{"issue":"5","key":"303_CR2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-005-0095-3","volume":"57","author":"T Okusaka","year":"2006","unstructured":"Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006;57(5):647\u201353. Epub 2005 Sep 2.","journal-title":"Cancer Chemother Pharmacol"},{"key":"303_CR3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008352123009","volume":"12","author":"M Penz","year":"2001","unstructured":"Penz M, Kornek GV, Raderer M, et al. II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001;12:183\u20136.","journal-title":"Ann Oncol."},{"key":"303_CR4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000070622","volume":"49","author":"MH Lin","year":"2003","unstructured":"Lin MH, Chen JS, Chen HH, Su WC. A phase II trial of gemcitabine in the treatment of advanced bile duct and periamullar carcinomas. Chemotherapy. 2003;49:154\u20138.","journal-title":"Chemotherapy."},{"key":"303_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381. doi: 10.1056\/NEJMoa0908721 .","journal-title":"N Engl J Med"},{"key":"303_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469\u201374. doi: 10.1038\/sj.bjc.6605779 . Epub 2010 Jul 13.","journal-title":"Br J Cancer."},{"key":"303_CR7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548\u201357.","journal-title":"Anticancer Drugs."},{"key":"303_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849\u201355. doi: 10.1007\/s00280-007-0673-7 . Epub 2008 Jan 23.","journal-title":"Cancer Chemother Pharmacol."},{"key":"303_CR9","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/cas.12218","volume":"104","author":"C Morizane","year":"2013","unstructured":"Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104:1211\u20136. doi: 10.1111\/cas.12218 . Epub 2013 Jul 25.","journal-title":"Cancer Sci."},{"key":"303_CR10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1245\/s10434-012-2312-8","volume":"20","author":"A Kato","year":"2013","unstructured":"Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318\u201324.","journal-title":"Ann Surg Oncol"},{"key":"303_CR11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7819-5-36","volume":"5","author":"MW Slupski","year":"2007","unstructured":"Slupski MW, Szczylik C, Jasinski MK. Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol. 2007;5:36.","journal-title":"World J Surg Oncol"},{"key":"303_CR12","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.3748\/wjg.v19.i40.6934PMCID:PMC3812497","volume":"19","author":"Y Oshiro","year":"2013","unstructured":"Oshiro Y, Takahashi K, Sasaki R, Kondo T, Sakashita S, Ohkohchi N. Adjuvant surgery for advanced extrahepatic cholangiocarcinoma. World J Gastroenterol. 2013;19:6934\u20138. doi: 10.3748\/wjg.v19.i40.6934PMCID:PMC3812497 . Published online Oct 28, 2013.","journal-title":"World J Gastroenterol"},{"key":"303_CR13","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.3748\/wjg.15.4593","volume":"15","author":"SH Kim","year":"2009","unstructured":"Kim SH, Kim IH, Kim SW, Lee SO. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma. World J Gastroenterol. 2009;15:4593\u20135.","journal-title":"World J Gastroenterol"},{"key":"303_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-009-1055-0","volume":"65","author":"A Sharma","year":"2010","unstructured":"Sharma A, Mohanti B, Raina V, Shukla N, Pal S, Dwary A, et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol. 2010;65:497\u2013502. doi: 10.1007\/s00280-009-1055-0 . Epub 2009 Jul 3.","journal-title":"Cancer Chemother Pharmacol."},{"key":"303_CR15","first-page":"106","volume":"5","author":"D Moussata","year":"2012","unstructured":"Moussata D, Bessayah A, Chauvenet M, Stroeymeyt K, Boschetti G, Cotte E, et al. A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma. Cancer Res. 2012;5:106\u20138.","journal-title":"Cancer Res."},{"issue":"6","key":"303_CR16","doi-asserted-by":"publisher","first-page":"E88","DOI":"10.3978\/j.issn.2078-6891.2014.051","volume":"5","author":"EJ Walker","year":"2014","unstructured":"Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol. 2014;5(6):E88\u201395. doi: 10.3978\/j.issn.2078-6891.2014.051 .","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"303_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5009\/gnl.2013.7.3.371","volume":"7","author":"JH Lim","year":"2013","unstructured":"Lim JH, Ryu JK, Choi YJ, Kwon J, Kim JY, Lee YB, et al. A case of common bile duct cancer that completely responded to combination chemotherapy of gemcitabine and TS-1. Gut Liver. 2013;7(3):371\u20136. doi: 10.5009\/gnl.2013.7.3.371 . Epub 2013 May 13.","journal-title":"Gut Liver"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-017-0303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40792-017-0303-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-017-0303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T06:22:19Z","timestamp":1498371739000},"score":1,"resource":{"primary":{"URL":"http:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-017-0303-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1186\/s40792-017-0303-5","relation":{},"ISSN":["2198-7793"],"issn-type":[{"type":"electronic","value":"2198-7793"}],"subject":[],"published":{"date-parts":[[2017,2,12]]},"article-number":"26"}}